Novo readies a big PhIII program for diabetes drug semaglutide; Sucampo inks deal to acquire R-Tech Ueno;

@FierceBiotech: TSRI researchers spotlight a hidden cause of antibiotics resistance. Story from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: Immatics, MD Anderson partner on a $60M immuno-oncology T-cell spinout. News | Follow @JohnCFierce

> Novo Nordisk ($NVO) said today that it is prepared to launch a major Phase III program for semaglutide, an oral  GLP-1 diabetes drug. It's a big commitment. The first study started in Q1 of next year, with investigators studying three doses of 3 mg, 7 mg and 14 mg compared to sitagliptin. And later that year 6 more studies will get started as Novo lays the foundation for a new drug application with data from some 8,000 patients. The Phase III plan follows a promising Phase II trial and discussions with regulatory officials. Release

> Sucampo Pharmaceuticals has struck a deal to buy Japan's R-Tech Ueno in a deal valued at $276 million. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Startup wins $9.4M Series A to back speedy handheld vital sign scanner. Article | Follow @FierceMedDev

@VarunSaxena2: Medtronic to buy Twelve for $408M+, joining Abbott and Edwards on the transcatheter mitral valve bandwagon. Report | Follow @VarunSaxena2

@EmilyWFierce: Readers weighed in on who $AGN should buy next. Find out who emerged the winner. More from FiercePharma | Follow @EmilyWFierce

> GE lends radiology tech to Philadelphia hospital in contract deal. More

> Noninvasive, point-of-care kidney monitor startup raises $22.4M to get to market. Story

> AirXpanders' tissue expander for breast reconstruction meets primary endpoint. Article

Pharma News

@FiercePharma: UPDATED: With vote approaching, Perrigo chief slams Mylan's 'troubling' values. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Shire rejigs manufacturing deal to step up Cinryze production. Story | Follow @CarlyHFierce

> Eli Lilly pops the bubbly on U.S. Alimta patent victory. More

> U.S. patent office puts new Copaxone's IP shield under the lens. Article

Biotech Research News

> New method uses coated gold nanorods to treat pain. Item

> UCSF cardiology chief builds a case for two new targets for heart drugs. More

> UC Berkeley team says brown fat implants may effectively tackle obesity. Report

> TSRI researchers spotlight a hidden cause of antibiotics resistance. Article

> MSK: 'This is what the future of precision medicine looks like.' Story

Diagnostics News

> Sequenom strikes liquid biopsy research deal with UC San Diego Moores. Item

> Roche shops around for sequencing tech with Lumora buy. More

> Illumina makes moves in China with Burning Rock cancer Dx deal. Report

> Roche's M&A party rages on with Kapa Biosystems deal. Story

> Guardant Health teams with Flatiron for liquid biopsy-based drug development platform. Article

Pharma Marketing News

> Novo pulls blockbuster diabetes med Victoza off the Type 1 track. Report

> Eli Lilly slaps down Teva's challenge to Alimta exclusivity. Item

> AstraZeneca uses snails and overstuffed luggage to push OIC awareness--and its branded solution. Article

> Boehringer Ingelheim partners with telenovela for diabetes storyline. News

> Can Sprout's Addyi shrug off serious side effects? These blockbusters did. Story

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.